A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
A Phase Ⅱ, open-label, single-arm study to assess the safety, tolerability, and efficacy of
Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer.
Phase:
N/A
Details
Lead Sponsor:
The Affiliated Hospital of Xuzhou Medical University